FDA seeks support for reorganization of cancer programs, but debate continues.
In a letter, ASCO reaffirms its views on oncology consolidation at FDA.
Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.
Board approves continuation of partnerships between minority institutions and cancer centers for research, training, and outreach.
Duke recruits Judd Moul as chief of urology.
Foundation offers funds for mesothelioma research.
Other NCI funding opportunities listed.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - In the epicenter of the measles outbreak, “love thy neighbor” does not extend to vaccination rates
A dispatch from Lancaster County - As Iowa goes blue, incoming Gov. Rob Sand and Sen. Josh Turek offer plans to address the state’s “cancer crisis”
- Anthony El-Khoueiry named director of USC Norris
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - David Hohn, former president and CEO of Roswell Park, dies at 84









